Bionano Genomics, Inc.

BNGO - Financial Snapshot

Metrics for BNGO

Price $1.2
Shares Outstanding 9.68M
All-Time Low $1.21
52-Week Low $1.21

Balance Statement Metrics

Net Cash / Share $0
cashValuePerShare = (Cash + Short Term Investments - Total Liabilities) / Shares Outstanding
Net Current Assets / Share $2.02
netCurrentAssetsPerShare = (Current Assets - Total Liabilities) / Shares Outstanding
Net Tangible Assets / Share $4.56
netTangibleAssetsPerShare = (Total Assets - Intangibles - Total Liabilities) / Shares Outstanding
Shares Outstanding Ave Change (Annual) 56.93%
Shares Δ YoY 144.63%

Income Metrics

Max Earning Power / Share $-5.64
maxEarningPowerPerShare = (EBITDA / EP_MULTIPLIER) / Shares Outstanding
Adjusted Earning Power $-8.37
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
Non-Cash Charges to Market Cap 19.29%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
Data as of: Price 02-03-26 16:00 ET, Balance Sheet 2025-09-30, Income Statement 2025-09-30, Cash Flow 2025-09-30

Indicators

Dividend indicators Value Date
Pays Dividend No 2-1-2026
Income indicators Value Date
EBITDA Positive No 2-1-2026
Net Income Positive No 2-1-2026
Avg CA Burn (Annual %) -41.67% 2-1-2026
Avg CA Burn (Quarterly %) 1.79% 2-1-2026

Shares Outstanding Changes

Date Shares Outstanding Delta
2025-09-25 9,680,265 +4,925,000
2025-09-22 4,755,265 +74,265
2025-08-19 4,681,000 +1,317,000

Short Interest Changes

Latest short interest: 1,054,082 shares (10.36% of float) | Days to cover: 6.19

Date Short Interest Delta Δ %
2026-02-03 1,054,082 shares +0 +0.00%
2026-02-02 1,054,082 shares +0 +0.00%
2026-01-30 1,054,082 shares None

Interesting Volume Days

Volume/ratio use shares outstanding as of the event date (frozen).

Date Volume Shares Outstanding Volume / Shares Price
No interesting volume events

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.